Dr. Dirk Hoffmann (A03) has been awarded the MTZ Award for Systems Medicine 2026 in recognition of his outstanding research on malignant brain tumors. His work provides important impulses for the development of novel therapeutic strategies against glioblastomas. His research focuses on the molecular and cellular mechanisms of glioblastoma, with particular emphasis on tumor heterogeneity, therapy resistance, and the identification of new biomarkers and targeted therapeutic approaches. During his doctoral studies, he investigated the communication and oncogenic properties of glioblastoma cells that are interconnected through tumor microtubes—an essential mechanism underlying therapy resistance. By combining single-cell–resolved and bulk multi‑omics analyses, he deciphered the molecular profile of these cellular networks and derived a network signature that was validated as a prognostic biomarker across several independent patient cohorts and is currently being evaluated in prospective clinical studies. In addition, his research is closely integrated with clinical trials on molecularly targeted therapeutic strategies, in which he identifies and validates prognostic and predictive biomarkers through retrospective multi‑omics analyses.
The MTZ Award for Systems Medicine, presented by the independent MTZ Foundation under the patronage of the Federal Ministry for Research, Technology and Space (BMFTR), is among the most prestigious German early‑career awards in medical systems biology and systems medicine. It honors exceptional dissertations that apply interdisciplinary approaches to investigate complex biological systems using molecular‑genetic, clinical, mathematical, or computational methods.
Dirk Hoffmann is also the recipient of the Richtzenhain Doctoral Prize (2025), in recognition of his outstanding doctoral thesis.